Max Baumann, Co-Founder and Head of Execution of Treehill Partners, discusses what investors, drug developers, and the rest of the life science sector can do to prepare for the Trump/RFK era. The arrival of a new US administration generates significant industry-wide speculation and anticipation regarding new policies and agendas that may impact not only pharma and … Continue reading Expert opinion on life sciences in a Trump/RFK era